靶向成纤维细胞活化蛋白PET显像剂的研究进展

莫纯威; 徐万帮; 唐刚华; 莫纯威; 徐万帮; 唐刚华

doi:10.3760/cma.j.cn121381-202203029-00251

[1]

Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy[J]. Proteomics Clin ApplProteomics Clin Appl, 2014, 8(5/6): 454-463. doi: 10.1002/prca.201300095

[2]

高媛, 武越歆, 韩莹莹, 等. 细胞外基质与肿瘤相关成纤维细胞[J]. 生物化学与生物物理进展, 2017, 44(8): 660-671. doi: 10.16476/j.pibb.2017.0251
Gao Y, Wu YX, Han YY, et al. Extracellular matrix and cancer-associated fibroblasts[J]. Prog Biochem BiophysProg Biochem Biophys, 2017, 44(8): 660-671. doi: 10.16476/j.pibb.2017.0251

[3]

Zi FM, He JS, He DH, et al. Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review)[J]. Mol Med RepMol Med Rep, 2015, 11(5): 3203-3211. doi: 10.3892/mmr.2015.3197

[4]

Koustoulidou S, Hoorens MWH, Dalm SU, et al. Cancer-associated fibroblasts as players in cancer development and progression and their role in targeted radionuclide imaging and therapy[J/OL]. Cancers, 2021, 13(5): 1100[2022-03-22]. https://www.mdpi.com/2072-6694/13/5/1100. DOI: 10.3390/cancers13051100.

[5]

Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts[J]. J Clin OncolJ Clin Oncol, 1994, 12(6): 1193-1203. doi: 10.1200/JCO.1994.12.6.1193

[6]

Pandya DN, Sinha A, Yuan H, et al. Imaging of fibroblast activation protein alpha expression in a preclinical mouse model of glioma using positron emission tomography[J/OL]. Molecules, 2020, 25(16): 3672[2022-03-22]. https://www.mdpi.com/1420-3049/25/16/3672. DOI: 10.3390/molecules25163672.

[7]

Hintz HM, Gallant JP, Vander Griend DJ, et al. Imaging fibroblast activation protein alpha improves diagnosis of metastatic prostate cancer with positron emission tomography[J]. Clin Cancer ResClin Cancer Res, 2020, 26(18): 4882-4891. doi: 10.1158/1078-0432.CCR-20-1358

[8]

Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl MedJ Nucl Med, 2018, 59(9): 1423-1429. doi: 10.2967/jnumed.118.210435

[9]

Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl MedJ Nucl Med, 2018, 59(9): 1415-1422. doi: 10.2967/jnumed.118.210443

[10]

Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention[J]. J Nucl MedJ Nucl Med, 2019, 60(10): 1421-1429. doi: 10.2967/jnumed.118.224469

[11]

Moon ES, Elvas F, Vliegen G, et al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA^5m chelators[J/OL]. EJNMMI Radiopharm Chem, 2020, 5(1): 19[2022-03-22]. https://ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-020-00102-z. DOI: 10.1186/s41181-020-00102-z.

[12]

Zhao L, Niu B, Fang JY, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of ⁶⁸Ga-labeled FAPI dimer[J]. J Nucl MedJ Nucl Med, 2022, 63(6): 862-868. doi: 10.2967/jnumed.121.263016

[13]

Lindner T, Altmann A, Giesel F, et al. ¹⁸F-labeled tracers targeting fibroblast activation protein[J/OL]. EJNMMI Radiopharm Chem, 2021, 6(1): 26[2022-03-22]. https://ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-021-00144-x. DOI: 10.1186/s41181-021-00144-x.

[14]

Toms J, Kogler J, Maschauer S, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an ¹⁸F-labeled FAP inhibitor[J]. J Nucl MedJ Nucl Med, 2020, 61(12): 1806-1813. doi: 10.2967/jnumed.120.242958

[15]

Wang SL, Zhou X, Xu XX, et al. Clinical translational evaluation of Al¹⁸F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(13): 4259-4271. doi: 10.1007/s00259-021-05470-5

[16]

Hu KZ, Wang LJ, Wu HB, et al. [¹⁸F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [⁶⁸Ga]Ga-FAPI-04[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2022, 49(8): 2833-2843. doi: 10.1007/s00259-021-05646-z

[17]

Hu KZ, Li JQ, Wang LJ, et al. Preclinical evaluation and pilot clinical study of [¹⁸F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts[J]. Acta Pharm Sin BActa Pharm Sin B, 2022, 12(2): 867-875. doi: 10.1016/j.apsb.2021.09.032

[18]

Huang JW, Fu LL, Hu KZ, et al. Automatic production and preliminary PET imaging of a new imaging agent [¹⁸F]AlF-FAPT[J/OL]. Front Oncol, 2022, 11: 802676[2022-03-22]. https://www.frontiersin.org/articles/10.3389/fonc.2021.802676/full. DOI: 10.3389/fonc.2021.802676.

[19]

Watabe T, Liu YW, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: ⁶⁴Cu- and ²²⁵Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models[J]. J Nucl MedJ Nucl Med, 2020, 61(4): 563-569. doi: 10.2967/jnumed.119.233122

[20]

Langer LBN, Hess A, Korkmaz Z, et al. Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [⁶⁸Ga]MHLL1[J/OL]. Theranostics, 2021, 11(16): 7755−7766[2022-03-22]. https://www.thno.org/v11p7755.htm. DOI: 10.7150/thno.51419.

[21]

Baum RP, Schuchardt C, Singh A, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using ¹⁷⁷Lu-FAP-2286: first-in-humans results[J]. J Nucl MedJ Nucl Med, 2022, 63(3): 415-423. doi: 10.2967/jnumed.120.259192

[22]

Chen HJ, Pang YZ, Wu JX, et al. Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2020, 47(8): 1820-1832. doi: 10.1007/s00259-020-04769-z

[23]

Lan LJ, Liu HX, Wang YW, et al. The potential utility of [⁶⁸Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [¹⁸F]FDG[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2022, 49(3): 963-979. doi: 10.1007/s00259-021-05522-w

[24]

Hathi DK, Jones EF. ⁶⁸Ga FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J/OL]. Radiol Imaging Cancer, 2019, 1(1): e194003[2022-03-22]. https://pubs.rsna.org/doi/10.1148/rycan.2019194003. DOI: 10.1148/rycan.2019194003.

[25]

Chen HJ, Zhao L, Ruan D, et al. Usefulness of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [¹⁸F]FDG PET/CT findings[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(1): 73-86. doi: 10.1007/s00259-020-04940-6

[26]

Ballal S, Yadav MP, Moon ES, et al. Biodistribution, pharmacokinetics, dosimetry of [⁶⁸Ga]Ga-DOTA. SA. FAPi, and the head-to-head comparison with [¹⁸F]F-FDG PET/CT in patients with various cancers[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(6): 1915-1931. doi: 10.1007/s00259-020-05132-y

[27]

Röhrich M, Loktev A, Wefers AK, et al. IDH-wildtype glioblastomas and grade Ⅲ/Ⅳ IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2019, 46(12): 2569-2580. doi: 10.1007/s00259-019-04444-y

[28]

Röhrich M, Floca R, Loi L, et al. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas[J]. Eur J RadiolEur J Radiol, 2020, 127: 109021-. doi: 10.1016/j.ejrad.2020.109021

[29]

Syed M, Flechsig P, Liermann J, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2020, 47(12): 2836-2845. doi: 10.1007/s00259-020-04859-y

[30]

Wang LJ, Tang GH, Hu KZ, et al. Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in the evaluation of advanced lung cancer[J]. RadiologyRadiology, 2022, 303(1): 191-199. doi: 10.1148/radiol.211424

[31]

Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET/CT using either ¹⁸F-AlF or cold-kit ⁶⁸Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients[J]. J Nucl MedJ Nucl Med, 2021, 62(2): 201-207. doi: 10.2967/jnumed.120.245084

[32]

Li YC, Lin XQ, Li Y, et al. Clinical utility of f-18 labeled fibroblast activation protein inhibitor (FAPI) for primary staging in lung adenocarcinoma: a prospective study[J]. Mol Imaging BiolMol Imaging Biol, 2022, 24(2): 309-320. doi: 10.1007/s11307-021-01679-w

[33]

Ristau J, Giesel FL, Haefner MF, et al. Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer[J]. Mol Imaging BiolMol Imaging Biol, 2020, 22(6): 1495-1500. doi: 10.1007/s11307-020-01548-y

[34]

Pang YZ, Zhao L, Luo ZM, et al. Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG uptake in gastric, duodenal, and colorectal cancers[J]. RadiologyRadiology, 2021, 298(2): 393-402. doi: 10.1148/radiol.2020203275

[35]

Koerber SA, Staudinger F, Kratochwil C, et al. The role of ⁶⁸Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience[J]. J Nucl MedJ Nucl Med, 2020, 61(9): 1331-1336. doi: 10.2967/jnumed.119.237016

[36]

Shi XM, Xing HQ, Yang XB, et al. Fibroblast imaging of hepatic carcinoma with ⁶⁸Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(1): 196-203. doi: 10.1007/s00259-020-04882-z

[37]

Shi XM, Xing HQ, Yang XB, et al. Comparison of PET imaging of activated fibroblasts and ¹⁸F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(5): 1593-1603. doi: 10.1007/s00259-020-05070-9

[38]

Röhrich M, Naumann P, Giesel FL, et al. Impact of ⁶⁸Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas[J]. J Nucl MedJ Nucl Med, 2021, 62(6): 779-786. doi: 10.2967/jnumed.120.253062

[39]

Kömek H, Can C, Güzel Y, et al. ⁶⁸Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the ¹⁸F-FDG PET/CT[J]. Ann Nucl MedAnn Nucl Med, 2021, 35(6): 744-752. doi: 10.1007/s12149-021-01616-5

[40]

Dendl K, Koerber SA, Finck R, et al. ⁶⁸Ga-FAPI-PET/CT in patients with various gynecological malignancies[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(12): 4089-4100. doi: 10.1007/s00259-021-05378-0

[41]

Elboga U, Sahin E, Kus T, et al. Superiority of ⁶⁸Ga-FAPI PET/CT scan in detecting additional lesions compared to ¹⁸FDG PET/CT scan in breast cancer[J]. Ann Nucl MedAnn Nucl Med, 2021, 35(12): 1321-1331. doi: 10.1007/s12149-021-01672-x

[42]

Kessler L, Ferdinandus J, Hirmas N, et al. ⁶⁸Ga-FAPI as a diagnostic tool in sarcoma: data from the ⁶⁸Ga-FAPI PET prospective observational trial[J]. J Nucl MedJ Nucl Med, 2022, 63(1): 89-95. doi: 10.2967/jnumed.121.262096

[43]

Koerber SA, Finck R, Dendl K, et al. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(12): 3918-3924. doi: 10.1007/s00259-021-05374-4

[44]

Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction[J]. J Mol Cell CardiolJ Mol Cell Cardiol, 2015, 87: 194-203. doi: 10.1016/j.yjmcc.2015.08.016

[45]

Varasteh Z, Mohanta S, Robu S, et al. Molecular imaging of fibroblast activity after myocardial infarction using a ⁶⁸Ga-labeled fibroblast activation protein inhibitor, FAPI-04[J]. J Nucl MedJ Nucl Med, 2019, 60(12): 1743-1749. doi: 10.2967/jnumed.119.226993

[46]

Heckmann MB, Reinhardt F, Finke D, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease[J]. Circ Cardiovasc ImagingCirc Cardiovasc Imaging, 2020, 13(9): e010628-. doi: 10.1161/CIRCIMAGING.120.010628

[47]

Siebermair J, Köhler MI, Kupusovic J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling[J]. J Nucl CardiolJ Nucl Cardiol, 2021, 28(3): 812-821. doi: 10.1007/s12350-020-02307-w

[48]

Luo YP, Pan QQ, Yang HX, et al. Fibroblast activation protein-targeted PET/CT with ⁶⁸Ga-FAPI for imaging IgG4-related disease: comparison to ¹⁸F-FDG PET/CT[J]. J Nucl MedJ Nucl Med, 2021, 62(2): 266-271. doi: 10.2967/jnumed.120.244723

[49]

Schmidkonz C, Rauber S, Atzinger A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging[J]. Ann Rheum DisAnn Rheum Dis, 2020, 79(11): 1485-1491. doi: 10.1136/annrheumdis-2020-217408

[50]

Xu TT, Zhao Y, Ding HY, et al. [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(4): 1254-1255. doi: 10.1007/s00259-020-05028-x

[51]

Lindner T, Altmann A, Krämer S, et al. Design and development of ^99mTc-labeled FAPI tracers for SPECT imaging and ¹⁸⁸Re therapy[J]. J Nucl MedJ Nucl Med, 2020, 61(10): 1507-1513. doi: 10.2967/jnumed.119.239731

[52]

Ballal S, Yadav MP, Moon ES, et al. Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study[J]. ThyroidThyroid, 2022, 32(1): 65-77. doi: 10.1089/thy.2021.0412